Elevated Frequency of Diabetes Mellitus in Hospitalized Manic-Depressive Patients
Publication: American Journal of Psychiatry
Abstract
OBJECTIVE: Disturbance in glucose homeostasis in psychiatric populations has been suggested since the early part of this century. Increased comorbidity of diabetes mellitus in persons with major mood disorders has also been suggested. The goal of this study was to determine whether subjects diagnosed with bipolar disorder have an elevated rate of comorbid diabetes mellitus. METHOD: Three hundred forty-five hospitalized patients, aged 20–74 years, who met the DSM-III-R criteria for bipolar disorder, manic or mixed subtype, were evaluated for a comorbid diagnosis of diabetes mellitus. The frequency of diabetes mellitus in the study group was determined and compared with the expected frequency, calculated as a weighted average based on sex and age from national norms. Variables characterizing the course and severity of the affective disorder in the group of diabetic bipolar subjects and a group of nondiabetic age-matched bipolar subjects were compared. RESULTS: The prevalence of diabetes mellitus among these bipolar patients was 9.9%, significantly greater than expected from national norms (3.4%). The patients with comorbid diabetes mellitus had significantly more lifetime psychiatric hospitalizations than the nondiabetic subjects, but age at first hospitalization and duration of psychiatric disorder were similar in the two groups. CONCLUSIONS: The frequency of diabetes mellitus in hospitalized patients diagnosed with bipolar disorder is higher than in the general population. Manic-depressive patients with diabetes mellitus have a more severe course of illness, as indicated by a greater number of psychiatric hospitalizations. Possible reasons for this increased comorbidity include a genetic relationship between the disorders, a causal relationship in which hypercortisolemia induces diabetes or diabetic vascular lesions contribute to mania, an overlapping functional disturbance affecting similar regions of the brain, or the effect of psychotropic medications.
Abnormal glucose regulation in psychiatric disorders, including manic-depression, was a focus of discussion and research in the first half of this century (1–13). Most of the reports comprised series of cases that are difficult to interpret and included few individuals with manic-depression. Gildea et al. (14) reported elevated glucose tolerance test results after oral, but not intravenous, administration of dextrose to 30 manic-depressive subjects. Two other studies also found abnormalities in glucose regulation in patients with manic-depression; van der Velde and Gordon (15) reported increased frequencies of abnormal results on glucose tolerance tests in manic patients compared with schizophrenic patients, and Lilliker (16) reported increased rates of comorbid diabetes mellitus in patients diagnosed with manic-depressive disorder. Both of those reports were confounded by diagnostic systems that predated the separation of unipolar depression from manic-depressive disorder. The purpose of the current study was to evaluate whether patients diagnosed with bipolar disorder, manic or mixed subtype, according to the DSM-III-R criteria have a higher frequency of diabetes mellitus than the general population.
METHOD
Medical histories of 345 patients admitted to John Umstead Hospital who met the DSM-III-R criteria for bipolar disorder, manic or mixed subtype, were evaluated for a comorbid diagnosis of diabetes mellitus. John Umstead Hospital is a state psychiatric hospital serving 14 counties in the north central region of North Carolina. The vast majority of patients are admitted directly from either mental health centers or emergency rooms located within this region. Chi-square analyses comparing the presence or absence of diabetic comorbidity with sex, race (white versus black), and diagnostic subtype (manic versus mixed) were computed. The mean ages of the diabetic and nondiabetic patients within the study group were compared by means of t tests.
The frequency of diabetes mellitus in the U.S. population aged 20–74 years has been estimated at 3.4% (17), with a higher rate among blacks (5.2%) than among whites (3.2%). A higher rate of diagnosed diabetes in women (3.8%) than in men (2.9%) has also been suggested, although this difference reaches significance only within some age groups. To facilitate a comparison of the frequency of diabetes mellitus in persons with bipolar illness and in the general population, we restricted our study group to the racial composition and age range of the subjects in the study by Harris et al. (17). We categorized our restricted group according to the same race (black or white), sex, and age groups (i.e., ages 20–44, 45–54, 55–64, and 65–74 years) and calculated a weighted average for the expected frequency of diabetes in our entire study group by using the frequencies in each of the same subgroups within the Harris et al. comparison study. Using this overall estimate, we determined the expected number of subjects drawn from the general U.S. population in a similar-size group who would have a self-reported history of diabetes mellitus and compared the two groups using a goodness-of-fit chi-square analysis. The comparison study (17) that we used to determine those rates, like ours, did not distinguish between type I and type II diabetes mellitus. The overall frequency of type I diabetes mellitus relative to type II is low (18), and the majority of cases would be expected to represent type II.
Diabetic bipolar patients whose previous psychiatric histories were available were matched by age (within 4 years) to randomly selected nondiabetic bipolar patients from the total study group. Age at first psychiatric hospitalization and number of lifetime psychiatric hospitalizations were compared for the groups by means of Wilcoxon signed-ranks tests and a Bonferroni correction applied to significance levels. In addition, diagnostic subtypes (manic versus mixed) of the two groups were compared by means of chi-square tests.
RESULTS
The initial cohort included 357 patients meeting the DSM-III-R criteria for bipolar disorder, manic (N=309) or mixed (N=48) subtype. This group consisted of 172 men and 185 women. Two hundred twelve patients were white, 143 were black, one was Oriental, and one was American Indian. Their mean age was 42.1 years (SD=13.8, range=18–82).
The raw prevalence of diabetes mellitus in the initial cohort was 10.1% (N=36). These 36 patients had been diagnosed with diabetes mellitus before their current psychiatric hospitalization. Characteristics of the diabetic and nondiabetic patients are shown in Table 1. The results of chi-square analyses were not significant for diagnostic subtype (mixed versus manic), race (white versus black), or sex, but the difference in the mean ages of the diabetic and nondiabetic groups was significant.
To facilitate a comparison with the reported frequency of diabetes mellitus in the U.S. population, four patients under the age of 20 were excluded (none was diabetic), six patients 75 years of age or older were excluded (two of whom were diabetic), and the one Oriental patient and the one American Indian patient were excluded (neither was diabetic). The remaining group comprised 345 white and black subjects aged 20–74 years and represented 96.6% of the initial cohort. One hundred seventy subjects were male and 175 were female. Two hundred seven were white and 138 were black.
The frequency of diabetes mellitus in this final group aged 20–74 years was 9.9% (N=34). The expected frequency of diabetes mellitus, based on the calculated frequency weighted for age, sex, and race from the comparison study groups (17), was 3.5%, which is equivalent to 12 of 345 subjects, minimally higher than the 3.4% calculated in the entire cohort of the comparison study. The frequency of diabetes mellitus was significantly higher in our bipolar patients (χ2=41.80, df=1, p<0.001).
For the comparison of the diabetic and age-matched nondiabetic bipolar patients, complete psychiatric histories were obtained for 29 (81%) of the 36 diabetic patients (seven white men, five black men, seven white women, and 10 black women). Their mean age was 55.6 years (SD=10.3). Three of these subjects met the criteria for bipolar disorder, mixed subtype, and 26 for bipolar disorder, manic subtype. The mean age of the matched nondiabetic bipolar comparison patients was 55.6 years (SD=10.0). This group consisted of seven white men, four black men, 11 white women, and seven black women. Three of them met the DSM-III-R criteria for bipolar disorder, mixed, and 26 for bipolar disorder, manic. As expected, the mean ages of the two groups did not differ (t=–0.01, df=56, n.s.). The maximum age difference for matching nondiabetic patients to the diabetic patients was 4 years, but 27 (93%) of the 29 nondiabetic patients were matched to within 2 years of age. The groups did not differ with respect to manic subtype (χ2=0.19, df=1, n.s.), sex (χ2=0.00, df=1, n.s.), or race (χ2=0.63, df=1, n.s.).
The age at first psychiatric hospitalization in the diabetic subgroup (mean=34.0 years, SD=12.1) did not differ significantly from that of the matched nondiabetic group (mean=37.1 years, SD=10.8) (z=0.91, n.s.). However, the total number of psychiatric hospitalizations in the diabetic group (mean=10.9, SD=10.5) was significantly greater than that in the age-matched comparison group (mean=5.3, SD=5.2) (z=–2.26, p<0.05). The age at onset of diabetes mellitus could not be determined reliably in these patients.
DISCUSSION
The overall frequency of diabetes mellitus (10.1%) in our cohort of patients with bipolar disorder, manic and mixed subtypes, is similar to the 10% frequency reported by Lilliker (16). Although a direct comparison of our group with population norms may be limited by methodological differences and selection biases, this 10.1% rate of diabetes mellitus in our manic cohort is well above the rate in the general population (3.4%). In this study we based our comparison group on national frequency norms of previously diagnosed diabetes mellitus. Our study and the comparison study (17) used similar standards for the identification of diabetic histories. In the comparison study, rates of undiagnosed diabetes mellitus were also estimated by administering glucose tolerance tests to all subjects with no previous history of diabetes mellitus. When we use a comparison group that includes both previously diagnosed cases and previously undiagnosed cases, the frequency of diabetes mellitus in our bipolar study group is still greater than expected (χ2=6.99, df=1, p<0.01). Although we controlled for age and sex in our comparison groups, the possibility of other confounding variables was not excluded. Nevertheless, the frequency of diabetes mellitus in our cohort was well above the expected 3.5%. Possible explanations for this comorbidity include a genetic relationship between the two diseases, a causal relationship in which the development of diabetes mellitus or mania increases the risk of the development of the other disorder, or a functionally overlapping disturbance present in both diseases.
Each of these possibilities derives some support from our understanding of these diseases. Although the genetics of bipolar disorder is not well understood, there is a consensus that multiple genes are likely to be involved in the pathogenesis of manic-depression (19). The tyrosine hydroxylase-INS-insulin-like growth factor II gene cluster on the short arm of chromosome 11 has been implicated as a susceptibility locus for diabetes mellitus (20, 21). Although initial reports of the INS gene being a susceptibility locus for bipolar disorder (22) were subsequently discounted after a reanalysis of a larger sample (23), tyrosine hydroxylase markers have been shown to have some associations with bipolar disorder (24–26).
Although high rates of cardiovascular and peripheral vascular disease are well recognized in persons with diabetes mellitus, few studies have addressed the issue of cerebrovascular disease in diabetic subjects (27). Higher rates of lesions of small intraparenchymal cerebral vessels and focal infarction have been reported in diabetic patients (28–31). Those lesions have occurred mainly in areas with blood supply from direct midline or parasagittal arteries serving areas such as the base of the pons, thalamus, and basal ganglia (31). Although it is not known whether diabetes-related vascular lesions that occur in the brain can result in psychopathology, subcortical white matter lesions have also been observed in T2-weighted magnetic resonance imaging (MRI) scans in bipolar disorder (32–37). Moreover, diabetes mellitus has been implicated as a risk factor for similar hyperintensities on T2-weighted MRI scans (38).
Manic episodes might also predispose to the development of diabetes mellitus. Increased glucocorticoids have been reported to induce diabetes mellitus (39), and hypercortisolemia has been reported during depressive episodes (40–44) and, by some researchers, during manic or mixed episodes (45–50).
The two diseases may also affect similar systems or areas of the brain. Both diabetes mellitus and mania have associated disturbances of the hypothalamic-pituitary-adrenal axis, as reflected by high rates of nonsuppression of cortisol on the dexamethasone suppression test (51–54). Moreover, the suprachiasmatic nucleus of the hypothalamus has been implicated both in disturbances of the sleep-wake cycle noted during mania (55) and in the regulation of glucose metabolism (56).
Although the exact relationship between bipolar disorder and diabetes mellitus is not known, the association between these disorders is clinically relevant and underscores the importance of screening for diabetes mellitus in the bipolar population, particularly because earlier detection and control of diabetes mellitus is considered important for prevention of the medical comorbidity of diabetes mellitus and for prevention of cerebral microvascular disease that may exacerbate the course of bipolar disorder. For example, the greater frequency of serious episodes of mania requiring hospitalization among the diabetic manic patients in our study be due to cerebral microvascular disease. Moreover, psychotropic medication may further increase the risk of the development of diabetes, either directly or as a result of weight gain. Further controlled studies of the relationship of these two disorders are warranted.
Footnote
Presented in part at the Third International Conference on Bipolar Disorder, Pittsburgh, June 17, 1999. Received Aug. 21, 1998; revisions received Nov. 23, 1998, and March 19, 1999; accepted April 13, 1999. From the Department of Psychiatry and Behavioral Sciences, Duke University Medical Center; Durham, N.C.; and John Umstead Hospital. Address reprint requests to Dr. Cassidy, John Umstead Hospital, 1003 12th St., Butner, NC 27509
References
1.
Kooy FH: Hyperglycaemia in mental disorders. Brain 1919; 42:214–289
2.
Heidema ST: Blutzuckerbestimmungen bei psychiatrischen und neurologischen Patienten. Z Gesamte Neurologie und Psychiatrie 1919; 48:111–129
3.
Raphael T, Parsons JP: Blood sugar studies in dementia praecox and manic-depressive insanity. Arch Neurol Psychiatry 1921; 5:681–709
4.
Cowie DM, Parsons JP, Raphael T: Insulin and mental depression. Arch Neurol Psychiatry 1924; 12:522–533
5.
Craig RN: Blood sugar curves in certain mental disorders. Lancet 1927; 1:1925–1927
6.
Bogen D: Blutuntersuchungen der Clyclophreniker mit der biologischen Methode. Z Gesamte Neurologie und Psychiatrie 1928; 117:569–584
7.
Bowman KM, Kasanin J: The sugar content of the blood in emotional states. Arch Neurol Psychiatry 1929; 21:342–362
8.
McCowan PK, Quastel JH: Blood-sugar studies in abnormal mental states. J Ment Sci 1931; 77:525–548
9.
Whitehorn JC: The blood sugar in relation to emotional reactions. Am J Psychiatry 1934; 90:987–1005
10.
Diethelm O: Influence of emotions on dextrose tolerance. Arch Neurol Psychiatry 1936; 36:342–360
11.
Tod H, Jones MS: Studies on carbohydrate metabolism in nervous and mental disorders and depressive states. Edinburgh Med J 1937; 44:44–46
12.
Tod H: Studies on carbohydrate metabolism in nervous and mental disorders and depressive states. Edinburgh Med J 1936; 43:524–527
13.
McFarland RA, Goldstein H: The biochemistry of manic-depressive psychosis: a review. Am J Psychiatry 1939; 96:21–58
14.
Gildea EF, McLean VL, Man EB: Oral and intravenous dextrose tolerance curves of patients with manic-depressive psychosis. Arch Neurol Psychiatry 1943; 49:852–859
15.
van der Velde CD, Gordon MW: Manic-depressive illness, diabetes mellitus, and lithium carbonate. Arch Gen Psychiatry 1969; 21:478–485
16.
Lilliker S: Prevalence of diabetes in a manic-depressive population. Compr Psychiatry 1980; 21:270–275
17.
Harris MI, Hadden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20–74 yr. Diabetes 1987; 36:523–534
18.
Melton LJ, Palumbo PJ, Che CP: Incidence of diabetes mellitus by clinical type. Diabetes Care 1983; 6:75–86
19.
McInnis MG: Recent advances in the genetics of bipolar disorder. Psychiatr Annals 1997; 27:482–488
20.
Todd JA, Bain SC: A practical approach to identification of susceptibility genes for IDDM. Diabetes 1992; 41:1029–1034
21.
Faas S, Trucco M: The genes influencing the susceptibility to IDDM in humans. J Endocrinol Invest 1994; 17:477–495
22.
Egeland JA, Gerhard DS, Pauls DL, Sussex JN, Kidd KK, Allen CR, Hostetter AM, Housman DE: Bipolar affective disorders linked to DNA markers on chromosome 11. Nature 1987; 325:783–787
23.
Kelsoe JR, Ginns EI, Egeland JA, Gerhard DS, Goldstein AM, Bale SJ, Pauls DL, Long RT, Kidd KK, Conte G, Housman DE, Paul SM: Re-evaluation of the linkage relationship between chromosome 11p loci and the gene for bipolar affective disorder in the Old Order Amish. Nature 1989; 342:238–243
24.
Meloni R, Leboyer M, Bellivier F, Barbe B, Samolyk D, Allilaire JF, Mallet J: Association of manic-depressive illness with tyrosine hydroxylase microsatellite marker (letter). Lancet 1995; 345:932
25.
Todd RD, O’Malley KL: Population frequencies of tyrosine hydroxylase restriction fragment length polymorphisms in bipolar affective disorder. Biol Psychiatry 1989; 25:626–630
26.
Leboyer M, Malafosse A, Boularand S, Campion D, Gheysen F, Samolyk D, Henriksson B, Denise E, des Lauriers A, Lepine JP, Sarifian E, Clerget-Darpoux F, Mallet J: Tyrosine hydroxylase polymorphisms associated with manic-depressive illness (letter). Lancet 1990; 335:1219
27.
DeJong RN: The nervous system complication of diabetes mellitus, with special reference to cerebrovascular changes. J Nerv Ment Dis 1950; 111:181–206
28.
Bell ET: A postmortem study of vascular disease in diabetes. Arch Pathol 1952; 53:444–455
29.
Alex M, Baron EK, Goldenberg S, Blumenthal HT: An autopsy study of cerebrovascular accident in diabetes mellitus. Circulation 1962; 25:663–673
30.
Aronson SM, Aronson BE: Intracranial vascular lesion in diabetes mellitus. J Neuropathol Exp Neurol 1960; 19:152–153
31.
Aronson SM, Aronson BE: Intracranial vascular lesions in patients with diabetes mellitus. J Neuropathol Exp Neurol 1973; 32:183–196
32.
Dupont RM, Jernigan TL, Butters N, Delis D, Hesselink JR, Heindel W, Gillin JC: Subcortical abnormalities detected in bipolar affective disorder using magnetic resonance imaging. Arch Gen Psychiatry 1990; 47:55–59
33.
Swayze VW II, Andreasen NC, Alliger RJ, Ehrhardt JC, Yuh WT: Structural brain abnormalities in bipolar affective disorder: ventricular enlargement and focal signal hyperintensities. Arch Gen Psychiatry 1990; 47:1054–1059
34.
Figiel GS, Krishnan KRR, Rao VP, Doraiswamy M, Ellinwood EH, Nemeroff CB, Evans D, Boyko O: Subcortical hyperintensities on brain magnetic resonance imaging: a comparison of normal and bipolar subjects. J Neuropsychiatry 1991; 3:18–22
35.
Strakowski SM, Woods BT, Tohen M, Wilson DR, Douglass AW, Stoll AL: MRI subcortical signal hyperintensities in mania at first hospitalization. Biol Psychiatry 1993; 22:204–206
36.
McDonald WM, Krishnan KRR, Doraiswamy PR, Blazer D: The occurrence of subcortical hyperintensities in elderly subjects with mania. Psychiatry Res 1995; 40:785–788
37.
Ahearn EP, Steffens DC, Cassidy F, Van Meter SA, Provenzale JM, Seldin MF, Weisler RH, Krishnan KRR: Familial leukoencephalopathy in bipolar disorder. Am J Psychiatry 1998; 155:1605–1607
38.
Kertesz A, Black SE, Tokar G, Benke T, Carr T, Nicholson L: Periventricular and subcortical hyperintensities on magnetic resonance imaging: “rims, caps, and unidentified bright objects.” Arch Neurol 1988; 45:404–408
39.
National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28:1039–1057
40.
Board F, Wadeson R, Persy H: Depressive affect and endocrine functions. Arch Neurol Psychiatry 1957; 78:612–620
41.
Gibbons RD: Cortisol secretion in depressive illness. Arch Gen Psychiatry 1964; 10:572–575
42.
Rizzo ND, Fox HM, Laidlaw JC, Thorn GW: Concurrent observations of behavior changes and of adrenocortical variation in a cyclothymic patient during a period of 12 months. Ann Intern Med 1954; 41:798–815
43.
Bunney WE Jr, Hartmann EL, Mason JW: Study of a patient with 48-hour manic-depressive cycles. Arch Gen Psychiatry 1965; 12:619–625
44.
Kennedy SH, Tighe S, McVeyk G, Brown GM: Melatonin and cortisol “switches” during mania, depression and euthymia in a drug-free bipolar patient. J Nerv Ment Dis 1989; 177:203–205
45.
Platman SR, Fieve RR: Lithium carbonate and plasma cortisol response in affective disorders. Arch Gen Psychiatry 1968; 18:591–594
46.
Carpenter WC Jr, Bunney WE Jr: Diurnal rhythm of cortisol in mania. Arch Gen Psychiatry 1971; 25:270–273
47.
Sachar ED: Twenty-four hour cortisol secretory patterns in depressed and manic patients. Prog Brain Res 1975; 42:81–91
48.
Akesode A, Hendler N, Kowarski AA: A 24-hr monitoring of the integrated plasma concentration of aldosterone and cortisol in manic patients. Psychoneuroendocrinology 1976; 1:419–426
49.
Carroll BJ: Neuroendocrine function in mania, in Manic Illness. Edited by Shopsin B. New York, Raven Press, 1979, pp 163–176
50.
Cookson JC, Silverstone T, Williams S, Besser GM: Plasma cortisol levels in mania: associated clinical ratings and changes during treatment with haloperidol. Br J Psychiatry 1985; 146:498–502
51.
Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James NM, Kronfol Z, Lohr N, Steiner M, de Vigne JP, Young E: A specific laboratory test for the diagnosis of melancholia: standardization, validation, and clinical utility. Arch Gen Psychiatry 1981; 38:15–22
52.
Hudson JI, Hudson MS, Rothschild AJ, Vignati L, Schatzberg AF, Melby JC: Abnormal results of dexamethasone suppression tests in depressed patients with diabetes mellitus. Arch Gen Psychiatry 1984; 41:1086–1089
53.
Cameron OG, Kronfol Z, Greden JF, Carroll BJ: Hypothalamic-pituitary-adrenocortical activity in patients with diabetes mellitus. Arch Gen Psychiatry 1984; 41:1090–1095
54.
Cassidy F, Ritchie JC, Carroll BJ: Dexamethasone plasma concentration and cortisol response during manic episodes. Biol Psychiatry 1998; 43:747–754
55.
Ibuka N, Kawamura H: Loss of circadian sleep-wakefulness cycle in the rat by suprachiasmatic nucleus lesion. Brain Res 1975; 96:76–81
56.
Yamamoto H, Nagai K, Nakagawa H: Additional evidence that the suprachiasmatic nucleus is the center of regulation of insulin secretion and glucose homeostasis. Brain Res 1984; 304:237–241
Information & Authors
Information
Published In
History
Published online: 1 September 1999
Published in print: September 1999
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).